Clinical Decision Support for Septic Shock in the Emergency Department: A Cluster Randomized Trial
Abstract
BACKGROUND AND OBJECTIVES
Delays in septic shock diagnosis cause preventable mortality in children. Evidence is limited around early recognition strategies. The hypothesis was that clinical decision support (CDS) based on machine-learning predictive models would increase the proportion of children receiving septic shock treatment prior to shock onset.
METHODS
CDS was implemented in a prospective, stepped-wedge, cluster randomized trial in 4 pediatric emergency departments (EDs) over five 10-week periods. The CDS used models identifying children who did not yet have shock but were predicted to be at high risk based on electronic health record data at arrival and after 2 hours. Providers received CDS; effectiveness was evaluated in patients 60 days to 18 years with concern for sepsis. The primary outcome was antibiotic and bolus within 1 hour of sepsis suspicion. Secondary outcomes were time-to-antibiotic, hypotensive septic shock. Implementation outcomes were evaluated in qualitative interviews.
RESULTS
Of 200 354 ED encounters from March 16, 2022, to March 1, 2023, 1331 encounters met inclusion criteria (979 intervention, 352 control arms). Antibiotic and bolus within 1 hour occurred in 39.0% of patients in the intervention arm versus 38.9% of patients in the control arm (adjusted odds ratio [aOR]: 1.07 [0.61-1.88]). There was no difference in outcomes of shock (aOR: 1.12 [0.53-2.46]) or antibiotic timeliness (aHR: 0.85 [0.63-1.16]). Providers reported the CDS felt valuable…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.